Cargando…

Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms()

Cancer immunotherapy is a type of treatment that restores and stimulates human immune system to inhibit cancer growth or eradicate cancer. It serves as one of the latest systemic therapies, which has been approved to treat different types of cancer in patients. Nevertheless, the clinical response ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Qingfeng, Wang, Jiaxu, Liu, Wai Nam, Zhao, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529825/
https://www.ncbi.nlm.nih.gov/pubmed/31121491
http://dx.doi.org/10.1016/j.tranon.2019.04.020
_version_ 1783420490924163072
author Chen, Qingfeng
Wang, Jiaxu
Liu, Wai Nam
Zhao, Yue
author_facet Chen, Qingfeng
Wang, Jiaxu
Liu, Wai Nam
Zhao, Yue
author_sort Chen, Qingfeng
collection PubMed
description Cancer immunotherapy is a type of treatment that restores and stimulates human immune system to inhibit cancer growth or eradicate cancer. It serves as one of the latest systemic therapies, which has been approved to treat different types of cancer in patients. Nevertheless, the clinical response rate is unsatisfactory and the response observed is mostly a partial response in patients. Despite the continuous improvement and identification of novel cancer immunotherapy, there is a pressing need to establish a robust platform to evaluate the efficacy and safety of pre-clinical drugs, simulate the interaction between patients’ tumor and immune system, and predict patients’ responses to the treatment. In this review, we summarize the pros and cons of existing immuno-oncology assay platforms, especially the humanized mouse models for the screening of cancer immunotherapy drugs. In addition, various emerging trends and progress of utilizing humanized mouse models as the screening tool are discussed. Of note, humanized mouse models can also be used for further development of personalized precision medicines to treat cancer. Collectively, these highlight the significance of humanized mouse models as the important platform for the screening of next generation cancer immunotherapy in vivo.
format Online
Article
Text
id pubmed-6529825
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-65298252019-05-28 Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms() Chen, Qingfeng Wang, Jiaxu Liu, Wai Nam Zhao, Yue Transl Oncol Review article Cancer immunotherapy is a type of treatment that restores and stimulates human immune system to inhibit cancer growth or eradicate cancer. It serves as one of the latest systemic therapies, which has been approved to treat different types of cancer in patients. Nevertheless, the clinical response rate is unsatisfactory and the response observed is mostly a partial response in patients. Despite the continuous improvement and identification of novel cancer immunotherapy, there is a pressing need to establish a robust platform to evaluate the efficacy and safety of pre-clinical drugs, simulate the interaction between patients’ tumor and immune system, and predict patients’ responses to the treatment. In this review, we summarize the pros and cons of existing immuno-oncology assay platforms, especially the humanized mouse models for the screening of cancer immunotherapy drugs. In addition, various emerging trends and progress of utilizing humanized mouse models as the screening tool are discussed. Of note, humanized mouse models can also be used for further development of personalized precision medicines to treat cancer. Collectively, these highlight the significance of humanized mouse models as the important platform for the screening of next generation cancer immunotherapy in vivo. Neoplasia Press 2019-05-20 /pmc/articles/PMC6529825/ /pubmed/31121491 http://dx.doi.org/10.1016/j.tranon.2019.04.020 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review article
Chen, Qingfeng
Wang, Jiaxu
Liu, Wai Nam
Zhao, Yue
Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms()
title Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms()
title_full Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms()
title_fullStr Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms()
title_full_unstemmed Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms()
title_short Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms()
title_sort cancer immunotherapies and humanized mouse drug testing platforms()
topic Review article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529825/
https://www.ncbi.nlm.nih.gov/pubmed/31121491
http://dx.doi.org/10.1016/j.tranon.2019.04.020
work_keys_str_mv AT chenqingfeng cancerimmunotherapiesandhumanizedmousedrugtestingplatforms
AT wangjiaxu cancerimmunotherapiesandhumanizedmousedrugtestingplatforms
AT liuwainam cancerimmunotherapiesandhumanizedmousedrugtestingplatforms
AT zhaoyue cancerimmunotherapiesandhumanizedmousedrugtestingplatforms